CIK 0000914475 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 2.9 B | 1.5 B | ||
| Net income (USD) | 407.3 M | 37.0 M | ||
| Diluted EPS (USD/shares) | 4.67 | 1.56 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-10-07 | 3 | FORM 3 | 2026-09-28 |
| 2026-09-28 | 8-K | 8-K items 5.02 | 2026-09-25 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-15 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-14 | 144 | 144 | |
| 2026-09-14 | 144 | 144 | |
| 2026-09-10 | 4 | FORM 4 | 2026-09-09 |
| 2026-09-09 | 144 | 144 | |
| 2026-09-03 | 4 | FORM 4 | 2026-09-02 |
| 2026-08-05 | 4 | FORM 4 | 2026-08-04 |
| 2026-07-31 | S-8 | S-8 | |
| 2026-07-31 | 8-K/A | 8-K/A items 9.01 | 2026-05-14 |
| 2026-07-31 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-30 | 4 | FORM 4 | 2026-07-28 |
| 2026-07-30 | 8-K | 8-K items 2.02,9.01 | 2026-07-30 |
| 2026-07-27 | SCHEDULE 13G/A | SCHEDULE 13G/A |
Forms on file (last 1,000): 4 560, 144 169, 8-K 96, SC 13G/A 36, 10-Q 26, 4/A 16, S-8 POS 13, 3 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=NBIX (0.002 USD), /gw/filings/filings?ticker=NBIX&form=8-K, /gw/filings/facts?ticker=NBIX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange